<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2013070713889N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-12-22</date_registration>
      <primary_sponsor>Vice chancellor for research,Zahedan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of injection order of the Diphtheria-Pertussis-Tetanus vaccine and Hepatitis B vaccine on pain in infants</public_title>
      <acronym></acronym>
      <scientific_title>The comparison of injection order of the Diphtheria-Pertussis-Tetanus vaccine and Hepatitis B vaccine on pain response in infants</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-12-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>140</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/13626</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Other design features: The is a single-blind, randomized clinical trial study, so that observer evaluating pain response was not aware of which vaccine had been administrated. Random selection was performed through placing letters A and B in envelope which was numbered for each participant as follows: ask mother of infants select one of these letters, letters A and B indicated of Intervention and Control group respectively.</study_design>
      <phase>1</phase>
      <hc_freetext>The Pain of vaccine.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: First the 0.5ml Hepatitis B vaccine manufactured by Pasteur Institute of Iran injected intramuscularly and then the 0.5ml DTP vaccine manufactured by Pasteur Company of Indonesia injected intramuscularly. Intervention 2: Control group: Routine order administered.(First the 0.5ml DTP vaccine manufactured by Pasteur Company of Indonesia injected intramuscularly and then the 0.5ml Hepatitis B vaccine manufactured by Pasteur Institute of Iran injected intramuscularly).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link>http://www.magiran.com/magtoc.asp?mgID=6389&amp;Number=14&amp;Appendix=0&amp;l=en</results_url_link>
      <results_summary>        	Aims and Background: The most common invasive painful procedure during childhood is injective vaccination. Failure to relieve pain causes lack of timely referral for immunization and reduction of vaccine coverage. The purpose of this study was to determine the effect of injection order on infant''s pain response after diphtheria، pertussis، and tetanus (DTP) and hepatitis B vaccination.&lt;br /&gt;&#13;
&lt;br /&gt;&#13;
Methods and Materials: In this single-blind clinical trial study، 140 healthy infants with inclusion criteria at the age of 2 months referred to health centers of Zahedan city، Iran، during 2012 were randomly divided into two groups of control and intervention. In the control group، first the DTP vaccine and later، the hepatitis B vaccine were injected and in the intervention group، the order was vice versa. Using the Modified Behavioral Pain Scale (MBPS) and a demographic information checklist، the infant''s pain response was evaluated. Data were analyzed using descriptive statistics and independent t-test via SPSS15 software.&lt;br /&gt;&#13;
&lt;br /&gt;&#13;
Findings: The mean pain score after injecting hepatitis B vaccine was significantly less in the intervention group (7.12 ± 0.91) than injecting DTP vaccine in the control group (7.70 ± 0.62) (P = 0.001). The mean total pain score was significantly lower in the intervention group (7.59 ± 0.83) compared with the control group (8.27 ± 0.62) (P = 0.010).&lt;br /&gt;&#13;
&lt;br /&gt;&#13;
Conclusion: According to results of this study، to decrease pain during multiple immunizations in infants، injecting hepatitis B vaccine first and then، the DTP vaccine could be done.&lt;br /&gt;&#13;
&lt;br /&gt;&#13;
Keywords: Diphtheria, pertussis, and tetanus (DTP) vaccine, hepatitis B vaccine, pain, infants    </results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatihe Kerman Saravi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nursing and Midwifery - Mashahir Square - Zahedan</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 54 1241 1515</telephone>
        <email>Fatihe @yahoo.com</email>
        <affiliation>Zahedan University  of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hasan Robabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nursing and Midwifery - Mashahir Square - Zahedan</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 54 1244 8584</telephone>
        <email>harobabi@yahoo.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion Criteria: 1. Healthy two month-old infants of both sexes with complete consciousness. 2. No history of surgery or hospitalization 3. Absence of chills, fever, diarrhea, etc. Exclusion criteria: taking analgesic or sedative drug 24 hours before vaccination by the infant or her mother.</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>3 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M79.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>pain in limb</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: First the 0.5ml Hepatitis B vaccine manufactured by Pasteur Institute of Iran injected intramuscularly and then the 0.5ml DTP vaccine manufactured by Pasteur Company of Indonesia injected intramuscularly.</i_keyword>
      <i_keyword>Control group: Routine order administered.(First the 0.5ml DTP vaccine manufactured by Pasteur Company of Indonesia injected intramuscularly and then the 0.5ml Hepatitis B vaccine manufactured by Pasteur Institute of Iran injected intramuscularly)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Behavioral pain responses. Timepoint: Immediately after vaccine injection until 15 seconds. Method of measurement: Modified Behavioral Pain Scale (MBPS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Duration of crying. Timepoint: Immediately after vaccine injection up to time infants calm down or,maximum up to 3 minutes after injection. Method of measurement: Using stop watch(second).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research,Zahedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-09-26</approval_date>
        <contact_name>Ethics committee of Zahedan University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for research, Zahedan University of Medical Sciences -Dr Hesabi Square- Zahedan Zahedan  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
